Drug discovery is hard! Despite decades of efforts, there's still only one target in the DNA damage response with an approved inhibitor: PARP

REVIEW: CAR-engineered NK cells versus CAR T cells in treatment of glioblastoma; strength and flaws link.springer.com/article/10.100…

A highly innovative, potential breakthrough in synthetic biology: engineered receptor platform to activate specific cells based on their cell surface molecules, such as immune response to cancer nature.com/articles/s4158… nature UC San Francisco Kole Roybal Roybal Lab Parker Institute for Cancer Immunotherapy DanPiraner

REVIEW Epigenetics behind CD8+ T cell activation and exhaustion nature.com/articles/s4143…

Add custom text styling to your ggplot2 visualizations with ggtext, an extension that brings advanced text formatting options directly into your R plots. With ggtext, you can use Markdown and HTML to style plot text, allowing you to incorporate features like bold, italics,

Molecular profiling of mBRAFV600E mCRC Nature Medicine doi.org/10.1038/s41591… 🔎BEACON phs-3 👉No impact of CMS, BM subtypes, GA (incl. RNF43), MSI or TMB on efficacy 👉more benefit w/ MEKi in immune-activated tumors? 👉interesting analysis on acquired resistance mutations

Neoadjuvant nivolumab & relatlimab in locally advanced MSI CRC Nature Medicine doi.org/10.1038/s41591… 🔎NICHE-3 phs 2 👉PR 97%, MPR 92%, pCR 68% 👉only one recurrence 👉Gr 3–4 irAEs 10% 💪Impressive, we need to find the most effective, least toxic combination ESMO - Eur. Oncology

ctDNA-based MRD & survival in resectable CRC Nature Medicine doi.org/10.1038/s41591… 🔎CIRCULATE-🇯🇵 GALAXY, 2,240 pts 👉shorter DFS in MRD+ patients 👉Better outcome after sustained ctDNA clearance in response to ACT 🧐What else do we need to implement into clinical practice?

The relationship of physical activity and life expectancy bjsm.bmj.com/content/early/… Summary points from the paper: —Americans over the age of 40 could live an extra 5.3 years if all were as active as the top 25% of the population. — For the least active 25% of Americans, an extra

Adjuvant immunotherapy in pts with resected GC/GEJ cancer following pre-OP CTx with high risk for recurrence (ypN+m R1) doi.org/10.1016/j.anno… 🔎EORTC 1707 VESTIGE, 195 pts 👉DFS 11.4 vs 20.8 mo 🧐Nivolumab/ipilimumab does not improve DFS, CTx remains best option ESMO - Eur. Oncology

Ramucirumab/paclitaxel as switch maintenance vs continuation of FOLFOX HER2-negative GC/GEJ cancer The Lancet Oncology doi.org/10.1016/S1470-… 🔎ARMANI phs 3 👉mPFS 6·6 vs 3·5 mo 👉mOS 12·6 vs 10·4 mo 🧐switch maintenance could be an option for pts who are not eligible for

Concordance of ctDNA and tissue genomic profiling in biliary tract cancer Journal of Hepatology doi.org/10.1016/j.jhep… 👉concordance in 84.8%, 👉ctDNA revealed 🎯GA in 34.3% 👉high VAF in ctDNA associated w/ poor prognosis 🧐LB valuable option ESMO - Eur. Oncology EASL Education ILCA Cholangiocarcinoma Foundation

Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm An excellent review👇 nature.com/articles/s4157…

Happy to share our new paper from katherlab , led by Dyke Ferber , which was just published in Nature Communications. In-context learning enables general-purpose vision language models to perform well on medical image analysis tasks. We don't need to train a neural network at all - just

For readers interested in bispecific antibodies as cancer therapies, here's a comprehensive recent review nature.com/articles/s4157… rdcu.be/d1w34

The problem with "open #AI systems" is that they're not open. nature nature.com/articles/s4158… "We reveal a map of open AI which shows that.... [it] is highly dependent on the resources of a few large corporate actors, who effectively control the AI industry and the research

Nivolumab plus Ipilimumab in Microsatellite-Instability–High mCRC NEJM doi.org/10.1056/NEJMoa… 🔎CM 8HW phs-3, 303 pts 👉24-mo PFS: 72% vs 14% 👉AEs Gr 3/ 4: 23% vs 48% 💪Excellent outcome w/ ICI,incl pts with liver mets, mBraf... ESMO - Eur. Oncology

The effects of GLP-1 drug (semaglutide) on the proteome shows broad impact, potential relevance to many diseases beyond obesity nature.com/articles/s4159… Nature Medicine

Using multimodal A.I. to more accurately predict a person's risk of cancer (and other conditions) by combining proteomics and electronic health records nature.com/articles/s4225… Nima Aghaeepour Nature Machine Intelligence open-access

Discovery of a new biomarker (RNAPII) in cancer that denotes aggressiveness, increased risk of recurrence, shown in breast cancer and meningioma (<-Figure) Science Magazine science.org/doi/10.1126/sc…